SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 218 filers reported holding SAGE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $135,257,109 | -54.8% | 6,572,260 | +3.3% | 0.03% | -52.6% |
| Q2 2023 | $299,217,883 | +24.8% | 6,363,630 | +11.4% | 0.06% | +18.8% |
| Q1 2023 | $239,777,189 | +14.0% | 5,714,423 | +3.6% | 0.05% | +14.3% |
| Q4 2022 | $210,385,427 | +8.9% | 5,516,136 | +11.8% | 0.04% | +2.4% |
| Q3 2022 | $193,158,000 | +25.9% | 4,932,518 | +3.9% | 0.04% | +32.3% |
| Q2 2022 | $153,413,000 | -33.7% | 4,749,623 | -32.1% | 0.03% | -22.5% |
| Q1 2022 | $231,535,000 | -23.6% | 6,995,000 | -1.8% | 0.04% | -16.7% |
| Q4 2021 | $303,158,000 | +1.1% | 7,126,411 | +5.3% | 0.05% | -5.9% |
| Q3 2021 | $299,976,000 | -9.1% | 6,769,933 | +16.5% | 0.05% | -7.3% |
| Q2 2021 | $330,177,000 | -14.6% | 5,811,940 | +12.5% | 0.06% | -19.1% |
| Q1 2021 | $386,659,000 | +4.3% | 5,165,789 | +20.6% | 0.07% | 0.0% |
| Q4 2020 | $370,577,000 | +2442.0% | 4,283,629 | +1696.0% | 0.07% | +2166.7% |
| Q3 2020 | $14,578,000 | +142.9% | 238,508 | +65.2% | 0.00% | +200.0% |
| Q2 2020 | $6,001,000 | -91.5% | 144,347 | -85.2% | 0.00% | -93.3% |
| Q4 2019 | $70,429,000 | -74.8% | 975,613 | -51.0% | 0.02% | -76.2% |
| Q3 2019 | $279,069,000 | -30.4% | 1,989,227 | -9.2% | 0.06% | -29.2% |
| Q2 2019 | $400,907,000 | +14.2% | 2,189,672 | -0.8% | 0.09% | +11.2% |
| Q1 2019 | $351,080,000 | +90.7% | 2,207,361 | +14.9% | 0.08% | +73.9% |
| Q4 2018 | $184,093,000 | -33.9% | 1,921,835 | -2.5% | 0.05% | -22.0% |
| Q3 2018 | $278,372,000 | -10.2% | 1,970,770 | -0.5% | 0.06% | -14.5% |
| Q2 2018 | $310,163,000 | -15.1% | 1,981,504 | -12.7% | 0.07% | -16.9% |
| Q1 2018 | $365,390,000 | +7.0% | 2,268,522 | +9.6% | 0.08% | +10.7% |
| Q4 2017 | $341,556,000 | +222.6% | 2,069,103 | +21.8% | 0.08% | +212.5% |
| Q3 2017 | $105,860,000 | -16.1% | 1,699,209 | +7.2% | 0.02% | -20.0% |
| Q2 2017 | $126,185,000 | – | 1,584,449 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 475,600 | $15,362,000 | 5.31% |
| Integral Health Asset Management, LLC | 412,257 | $13,316,000 | 2.74% |
| Palo Alto Investors LP | 851,409 | $27,501,000 | 2.40% |
| Boxer Capital, LLC | 1,094,000 | $35,336,000 | 2.24% |
| DAFNA Capital Management LLC | 180,306 | $5,824,000 | 1.59% |
| Ikarian Capital, LLC | 250,000 | $8,075,000 | 1.47% |
| Bellevue Group AG | 2,973,178 | $96,034,000 | 1.36% |
| SECTOR GAMMA AS | 118,476 | $3,827,000 | 0.86% |
| Artal Group S.A. | 450,000 | $14,535,000 | 0.78% |
| Diametric Capital, LP | 19,393 | $626,000 | 0.46% |